All sponsors

IDEAYA Biosciences $IDYA

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.9 months). See all sponsors →

Open IDEAYA Biosciences on the live radar map → 📅 $IDYA readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
IDE196
NCT05987332
P2/3Active, not recruitingMetastatic Uveal Melanoma4202027-01-15
IDE196
NCT03947385
P1/2RecruitingMetastatic Uveal Melanoma; Cutaneous Melanoma3362027-01-29 (+61 mo)
Darovasertib
NCT05907954
P2Active, not recruitingUveal Melanoma1602027-04-30 (+15 mo)
IDE849
NCT07174583
P1/2RecruitingSmall-cell Lung Cancer; Neuroendocrine Carcinomas2622029-07 (+2 mo)
Darovasertib
NCT07015190
P3RecruitingUveal Melanoma5202030-10 (+41 mo)
Darovasertib
NCT07804186
P3RecruitingUveal Melanoma4502034-03